Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

biolover Mar. 21 at 11:10 PM

$VKTX for ones whining about tirzapetide price cut including HSBS guy . Now $450 15 mg at Trump Rx. Go look at cash prices for other CV drugs. Repatha jardiance Farxiga ..:

0 · Reply

pjapak Mar. 21 at 8:22 PM

$VKTX This will be gone the day the buyer makes up it's mind to shell out 90% of BL's ask, whatever it is. It will be this year. Next yr the ask will be double.

2 · Reply

PeteMitchell1981 Mar. 21 at 7:43 PM

$VKTX Bourla and Ricks will end up offering massive amounts if Viking shares phase 3 in 2027. Im ok with that. If a deal happens, BL will make sure it’s worth while. I’m also ok with that

0 · Reply

NYG4ever Mar. 21 at 4:45 PM

$VKTX lost me at less than zero % chance - you also dont have any clue what is actually happening behind the scenes nor do any of us. You're preaching lol

1 · Reply

bavariaron Mar. 21 at 4:40 PM

$VKTX ** GLP-1 Drugs are changing how Americans eat. ** Food companies are racing to catch up. https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html?taid=69be8c0a227d84000121c9ef&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter VKTX Long-Term

0 · Reply

KnysnaNow Mar. 21 at 4:17 PM

$VKTX [1 of 2] @dagster01 Dagster- You are right! I would like to take this opportunity to thank you for writing your very succinct and truthful post. I know it was partially directed towards me and that is why I’m replying directly. If this was years ago, I would likely have been the person writing your post. But the world has change so very quickly and I guess my typical balanced demeanor has been affected by the chaos around us. Luckily, living in NYC I have been generally sheltered from the devastating trauma that many have dealt with over the last months, weeks, days. My guess is that the conversations I have had with friends over the past week+ just caught up with me prior to replying to the post: * Doctorate-level American friends strongly considering leaving the country or having already left (3). * Friends who have saved for two decades questioning if they should spend $80,000 a year to send their child to a college in 2027+.

2 · Reply

AStrokeOfLuck Mar. 21 at 3:58 PM

$NVO $LLY $VKTX

0 · Reply

biolover Mar. 21 at 2:58 PM

$VKTX when BL speaks , he is not conservative. He is sometimes as ass .. He Used to be different a couple of years ago. But one thing you don’t need to worry about , he is not caving in to BP. That is probably most critical as we he will get shareholders the best possible deal. I am happy Bourla called it “ crazy demands “. Otherwise Bourla would have bragged for years about stealing VK assets. BL is not VERVE CEO giving out great assets to Lilly for free

0 · Reply

biolover Mar. 21 at 2:53 PM

$VKTX TZP half life 5 days. Vk2835 8.5 days. It can make a difference. Particularly with orals that can accumulate. Could be more difficult to make TZP oral. We don’t know if $LLY attempted. If orfoglipron shows liver toxicity ( my estimate 1/300 pts ) …again If. Lilly will find itself behind here. $GPCR could show ALT > x5-10 at 1-100-200 .. will see. I could be wrong here. AZN orfor like molecule had one case of liver toxicity in phase 1. Look at exposure. I think VK2735 could be slightly exaggerated on this modeling as phase 2 had more females. But if it beats by 1% at 12 wks. It can make a difference long term. This is what $NVO needs.

0 · Reply

haupman Mar. 21 at 2:21 PM

$VKTX none of the pumper math has ever worked. If they go at it alone, they will have 175M shares outstanding because they need a lot more capital. 5% of $100B peak sales is just $5B. 3x revenue is $15B which is only $85/share. In 2031!!! If BL is turning down $70/share offers right now then he's an idiot.

1 · Reply

Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 5, 2026, 4:03 PM EST - 16 days ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Feb 23, 2026, 2:29 PM EST - 26 days ago

Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

Feb 14, 2026, 8:44 AM EST - 5 weeks ago

Viking Therapeutics: Full-Speed Ahead

Feb 13, 2026, 8:35 AM EST - 5 weeks ago

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential

Feb 12, 2026, 12:44 AM EST - 5 weeks ago

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 5:10 PM EST - 5 weeks ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 4:33 PM EST - 5 weeks ago

Viking Therapeutics Stock Climbs After Q4 Report: Details

Feb 11, 2026, 4:16 PM EST - 5 weeks ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 5, 2026, 6:03 PM EST - 6 weeks ago

The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short

Feb 4, 2026, 4:05 PM EST - 6 weeks ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 3, 2026, 1:27 PM EST - 6 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Jan 13, 2026, 1:35 AM EST - 2 months ago

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:19 PM EST - 2 months ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 2 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 2 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Jan 3, 2026, 10:00 AM EST - 2 months ago

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Jan 1, 2026, 2:13 AM EST - 2 months ago

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Dec 28, 2025, 9:40 AM EST - 2 months ago

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Dec 6, 2025, 8:57 AM EST - 3 months ago

Viking Therapeutics: Prepping For A Critical 2026

Nov 25, 2025, 4:05 PM EST - 4 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 1:58 PM EST - 4 months ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Nov 19, 2025, 4:48 AM EST - 4 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:55 AM EST - 4 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 4 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 5, 2025, 10:01 AM EST - 4 months ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Oct 29, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 23, 2025, 10:42 AM EDT - 5 months ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:05 AM EDT - 5 months ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 22, 2025, 7:33 PM EDT - 5 months ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 5 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 4, 2025, 9:44 AM EDT - 6 months ago

Viking Therapeutics: A Speculative Buy

Sep 28, 2025, 2:00 PM EDT - 6 months ago

Viking Therapeutics: Overdue For Gains

Sep 23, 2025, 1:53 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 22, 2025, 1:55 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 8, 2025, 5:43 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 23, 2025, 6:57 AM EDT - 7 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Aug 20, 2025, 8:52 PM EDT - 7 months ago

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 9:50 AM EDT - 7 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 7 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 7 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 2:44 PM EDT - 7 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 1:45 PM EDT - 7 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 7 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:05 PM EDT - 7 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

biolover Mar. 21 at 11:10 PM

$VKTX for ones whining about tirzapetide price cut including HSBS guy . Now $450 15 mg at Trump Rx. Go look at cash prices for other CV drugs. Repatha jardiance Farxiga ..:

0 · Reply

pjapak Mar. 21 at 8:22 PM

$VKTX This will be gone the day the buyer makes up it's mind to shell out 90% of BL's ask, whatever it is. It will be this year. Next yr the ask will be double.

2 · Reply

PeteMitchell1981 Mar. 21 at 7:43 PM

$VKTX Bourla and Ricks will end up offering massive amounts if Viking shares phase 3 in 2027. Im ok with that. If a deal happens, BL will make sure it’s worth while. I’m also ok with that

0 · Reply

NYG4ever Mar. 21 at 4:45 PM

$VKTX lost me at less than zero % chance - you also dont have any clue what is actually happening behind the scenes nor do any of us. You're preaching lol

1 · Reply

bavariaron Mar. 21 at 4:40 PM

0 · Reply

KnysnaNow Mar. 21 at 4:17 PM

2 · Reply

AStrokeOfLuck Mar. 21 at 3:58 PM

$NVO $LLY $VKTX

0 · Reply

biolover Mar. 21 at 2:58 PM

0 · Reply

biolover Mar. 21 at 2:53 PM

0 · Reply

haupman Mar. 21 at 2:21 PM

1 · Reply

ROZZ0384 Mar. 21 at 2:09 PM

$VKTX Preach on, Bag. Less than zero chance of a deal, any deal, at this SP. Maintenance readout might move it enough to make some kind of partnership palatable, certainly not enough for a full BO. BP not entertaining 500% stock premium deals. But a partnership not BL's first choice and he's made it clear hes not entertaining lowball offers. Grab a comfy spot on the couch 4Q'27

1 · Reply

Stockman824 Mar. 21 at 1:46 PM

$VKTX I would think it’s also better to be on the drug and eventually switch to maintenance then to have your entire digestive system severely altered by surgery. I’d rather start with the drugs. I have severe at times GERD and I have been on Prilosec and Pepcid for 8ish years. I’ve thought about surgeries (there are a couple different ones) but I dont want to go thru the stress. The Prilosec Pepcid works 90% of the time. If I get a flair I take 1 tums and things are fine.

0 · Reply

JIMMYDAMA Mar. 21 at 1:11 PM

$VKTX Just a quick real life reminder for those NOT on Obesity Meds, on a 10 day trip, last maintenance shot of Zep 9 days ago, hunger is back, like I was never on the drug. Purposely did not bring Zep as a test. I will be on this, (hopefully VK2735 Oral) for the rest of my life!! This category is not a take it and you are done drug. This is a Life altering forever drug. Ask anyone currently on obesity meds if they plan to quit, NO ONE will say yes. The TAM is HUGE, the money I’m saving on food is the $349 every 2 months for Zep. If you are on it YOU KNOW, if not ask someone who is! Very Encouraged and Bullish! GLTA!!

0 · Reply

leshgo Mar. 21 at 12:06 PM

$VKTX Also, don't sleep on VK2809. There's plenty of potential to monetize it through a partnership or an asset sale.😉

1 · Reply

leshgo Mar. 21 at 10:54 AM

$VKTX ⛔️ Disclaimer: This post is not based on facts; it is purely my personal opinion and speculation. Please do not use it as financial advice. Let's assume that multiple Big Pharma companies are throwing out lowball offers to acquire VKTX on the cheap, and BL (Brian Lian) is holding out for a premium, which is why a deal hasn't been made yet. From what I know, BL is a very conservative and cautious guy when he speaks. If someone like him lacked confidence in the pipeline, he would have sold VKTX at a discount a long time ago. But the fact that no deal has been made yet tells me BL has absolute conviction in his pipeline. He knows that once the Phase 3 and maintenance dosing data come out positive, the company's valuation will be significantly higher.

4 · Reply

Bagholding_VKTX Mar. 21 at 4:29 AM

$VKTX This is exactly why there has not been a deal yet made with Viking. A lot of people here have been advancing this thesis for a long time, I'm thinking most notably of @biolover Now we have confirmation of what has been said here. Big Pharmas are trying to leverage the current low share price of Viking and are sending offers based on today's share price. Not really on what VK2735 has the potential to become. This is a big, big, big mistake. They are basically penny-pinching here. Even if they paid 10x Viking's current valuation, at peak sales, they could break-even in a year. The reason why they are afraid to do so however is bad optics. See how Pfizer's management got clowned on for years after the Seagen deal? That's what they're trying to avoid. Again, massive mistake. This is what I like about Brian. As a shareholder, I KNOW for a fact that he will not let me down and accept a lowball offer. Hence, the "crazy demands" comment from Bourla in 2025. Extremely bullish.

3 · Reply

Bag_Holder_ Mar. 21 at 2:37 AM

$VKTX is this bad?

0 · Reply

Axadude Mar. 21 at 2:15 AM

$VKTX https://nypost.com/2026/03/20/health/how-glp-1-effectiveness-is-messing-up-new-drug-trials/?utm_campaign=iphone_nyp&utm_source=message_app

0 · Reply

robc11 Mar. 21 at 1:32 AM

$VKTX not sure if everyone saw this… per Adam Feinstein on X… https://x.com/adamfeuerstein/status/2035071283117895973?s=46&t=-ZehvxliKigvBLl71LeB8Q

0 · Reply

Axadude Mar. 21 at 1:26 AM

$VKTX Market Forecast: J.P. Morgan analysts have projected the global GLP-1 market to reach $71 billion by 2032. Other, more recent 2026 reports from the firm suggest the global incretin market (including GLP-1s) could reach $200 billion by 2030

0 · Reply

SlimyMango Mar. 21 at 1:12 AM

$VKTX Grabbed another 100 in the Roth under 32. Had to step away at work quick 😂

1 · Reply

oldmanrizzer Mar. 20 at 11:11 PM

$HIMS $NVO $LLY $VKTX GLP-1 stocks are cooked. Do we think they'll ever hit the heights at the start of the craze or even recover for that matter? Crazy how the weight loss industry generates billions upon billions of dollars yet the real money wants nothing to do with these stocks. I wish NVO could just get rid of the GLP1 business all together, layoff 50-60% more of the company and go back to focusing on their other products. The stock actually did better then. Soon there will about 100 companies producing GLP1 pills. I honestly don't like how this all transpired so quickly with so many analysts posting bearish sentiment that GLP1 is way overstated in demand.

4 · Reply

Market Cap	3.88B
Revenue (ttm)	0.00
Net Income (ttm)	-359.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,523,600
Avg Vol	2,997,278
Day's Range	N/A - N/A
Shares Out	115.55M
Stochastic %K	14%
Beta	0.75
Analysts	Strong Sell
Price Target	$92.56